Recently, the multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial of oral LW402 tablets for the evaluation of efficacy and safety in patients with non-segmental vitiligo has successfully enrolled its first patient. Sponsored by LWBP, this trial is led by Professor Lehong Xiang from Huashan Hospital Affiliated to Fudan University.
Vitiligo is a chronic autoimmune skin disease. Its core mechanism involves IFN-γ activating the JAK-STAT signaling pathway, which in turn mediates the attack of autoreactive CD8+ T cells on melanocytes, leading to well-defined white patches on the skin or hair. Current treatments mainly include topical corticosteroids, calcineurin inhibitors, and narrow-band ultraviolet B (NB-UVB) phototherapy, but these have limitations such as slow onset, incomplete repigmentation, and high relapse rates after discontinuation.
JAK inhibitors block the JAK-STAT pathway, inhibit the activation of autoreactive T cells and the survival of tissue-resident memory T cells, and have been shown in multiple studies to achieve clinical repigmentation.
LW402作为新一代高选择性口服JAK1抑制剂，有望为白癜风患者提供有效及安全的口服系统性治疗新选择。
关于LW402
LW402是由长森药业自主研发的新一代JAK1高选择性抑制剂，能有效控制自身免疫性疾病相关的炎症反应，用于类风湿关节炎、特应性皮炎、白癜风、斑秃等多个自身免疫疾病治疗。此前开展的临床研究结果显示，LW402起效迅速，一周即可显著改善患者炎症相关疗效指标，其数倍安全窗特征在多个已开展的临床试验中得到验证，显示了良好的安全性。
LW402发明专利获得中国及PCT发明专利授权，相关知识产权覆盖中国、北美、欧盟及亚太等全球主要国家及地区。
关于长森药业
长森药业成立于2012年，是由全球知名化学药物研发专家领衔的创新药研发公司。公司致力于自主研发国际领先的，拥有全球知识产权的创新药产品，满足临床未竟需求。公司聚焦抗免疫抗病毒、免疫抗肿瘤、自身免疫疾病等领域的创新药开发与产业化，已开展多个自主研发的小分子创新药项目（FIC，first in class），多个产品进入临床试验阶段，有希望成为相关领域的重大突破。